Oncology Main Article


Daiichi Sankyo Cancer Enterprise

Daiichi Sankyo Cancer Enterprise

The vision of Daiichi Sankyo Cancer Enterprise is to leverage our world-class, innovative science and push beyond traditional thinking in order to create meaningful treatments for patients with cancer. We are dedicated to transforming science into value for patients, and this sense of obligation informs everything we do.

Caliber of Science

Driven by an obligation to translate high-quality science into value for patients, the Daiichi Sankyo Cancer Enterprise is committed to becoming a world-class leader in oncology. Our teams of exceptional scientists share a passion for innovation and meticulous execution to advance the next generation of precision medicines.

Dynamic and Sustainable R&D Engine

The Daiichi Sankyo Cancer Enterprise portfolio is powered by our research engines:

  • Two laboratories for biologic/immuno-oncology and small molecules in Japan
  • Plexxikon Inc. – small molecule structure-guided R&D center in Berkeley, California

Focused and Prioritized Pipeline

Anchored by our investigational Antibody Drug Conjugate (ADC) and Acute Myeloid Leukemia (AML) Franchises, the Daiichi Sankyo Cancer Enterprise prioritized portfolio includes more than 20 ADCs, monoclonal antibodies and small molecules. 

Enhanced Capabilities Through Collaboration

To complement and expand our premier cadre of internal scientists, we are collaborating with leading academic and business partners to leverage cutting-edge science in new treatment modalities, disease biology, diagnostics and pipeline prioritization.

To learn more about Daiichi Sankyo Cancer Enterprise, click here.


ADC Franchise More Stories Content

More Stories

ADC Franchise

ADCs are a type of targeted cancer medicine that deliver chemotherapy (“payload”) directly to cancer cells via a linker attached to a monoclonal antibody.

read more ...